Market Overview

UPDATE: Piper Jaffray Initiates Orexigen at Overweight on Valuation, Outlook

Related OREX
2 Skyrocketing Biotech Stocks In A Stalling Market
What's Driving Orexigen Therapeutics Higher?

Piper Jaffray initiated coverage on Orexigen (NASDAQ: OREX) with an Overweight rating and a $10 price target.

Piper Jaffray commented, "We believe shares are overly discounted vs. peers due to the delayed approval of lead drug Contrave (3rd to market). In our view, Contrave's differentiated profile should position it well in what we anticipate to be a robust U.S. obesity Rx market, resulting in part from competitors' efforts with awareness and reimbursement. We see Contrave's efficacy in a broad set of patients, its likely “clean” label and scheduling, satisfactory patient experience with buproprion, and PCP-experienced partner (Takeda) as establishing competitive advantage and driving it to be a $0.5-$1.0B obesity drug and a shareholder “win.”"

Orexigen closed at $5.76 on Thursday.

Latest Ratings for OREX

DateFirmActionFromTo
Oct 2013Cowen & CompanyInitiates Coverage onOutperform
Jan 2013Piper JaffrayInitiates Coverage onOverweight
Oct 2012Jefferies & CompanyMaintainsHold

View More Analyst Ratings for OREX
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (OREX)

Around the Web, We're Loving...

Get Benzinga's Newsletters